Long-term follow-up of R-CHOP with bevacizumab as initial therapy for mantle cell lymphoma: Clinical and correlative results Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Lymphoma, Mantle-Cell

abstract

  • The addition of bevacizumab to the standard R-CHOP regimen did not appear to significantly improve efficacy beyond that observed from previous studies using R-CHOP alone. Therapeutic strategies that provide sustained inhibition on VEGF-related and VEGF-independent targets within the tumor microenvironment might further improve antiangiogenic effects and warrant further exploration in MCL.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.clml.2013.10.002

PubMed ID

  • 24373788

Additional Document Info

start page

  • 107

end page

  • 13

volume

  • 14

number

  • 2